Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary

Paratek Pharmaceuticals (Nasdaq: PRTK) announced on September 30, 2021, the granting of stock options to five new employees. This is part of the 2017 Inducement Plan, approved by the board, aimed at attracting talent. The total stock options amount to 9,700 shares at an exercise price of $4.86, vesting over four years. Additionally, 9,600 restricted stock units will vest after 36 months. Paratek is focused on life-saving therapies, including its commercial product NUZYRA for CABP and ABSSI, and has expanded its contract with BARDA to support the development of NUZYRA for pulmonary anthrax.

Positive

• Stock options granted to attract new talent, enhancing team capabilities.
• Collaboration with Zai Lab for NUZYRA in China, expanding market access.
• BARDA contract expanded to approximately $304 million, providing significant funding for NUZYRA.

Negative

• None.

BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced that on September 30, 2021, the Company granted stock options to five new employees of the Company. These awards were granted pursuant to the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, which was approved by the Company's board of directors on June 15, 2017, under Rule 5635(c)(4) of the NASDAQ Listing Rules, for equity grants to employees entering into employment or returning to employment after a bona fide period of non-employment with the Company, as an inducement material to such individuals entering into employment with the Company.

The stock options are to acquire, in the aggregate, 9,700 shares of the Company’s common stock at a per share exercise price of $4.86, the closing sales price on September 30, 2021, and shall vest over a four-year vesting period, under which 25% of the shares will vest after 12 months of employment, with the remaining shares vesting monthly thereafter over the remaining 36-month period, subject to the employee’s continuous service. The restricted stock units are to acquire, in the aggregate, 9,600 shares of the Company’s common stock and shall vest upon the conclusion of a 36-month vesting period, under which one hundred percent 100% of the restricted stock units will vest after 36 months of employment, subject to the employee’s continuous service. The stock options and restricted stock units are subject to the terms and conditions of the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, and the terms and conditions of the stock option agreement and restricted stock unit award agreement covering each grant.

About Paratek Pharmaceuticals, Inc.

Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical Company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use.

The Company’s lead commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in the U.S. for the treatment of adults with CABP and ABSSI. Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.

Paratek is also conducting a Phase 2b Study in a rare disease, Nontuberculous Mycobacterial (NTM) Pulmonary Disease caused by Mycobacterium abscessus Complex with NUZYRA. Paratek estimates this opportunity represents a potential $1.0 billion addressable market in the U.S.

Paratek exclusively licensed U.S. rights and rights to the greater China territory for SEYSARA® (sarecycline), a once-daily oral therapy for the treatment of moderate to severe acne vulgaris, to Almirall, LLC. Paratek retains the development and commercialization rights for sarecycline in the rest of the world.

In 2019, Paratek was awarded a contract from BARDA, valued at up to approximately $285 million, to support the development and U.S.-based manufacturing of NUZYRA for the treatment of pulmonary anthrax. In 2021, the BARDA contract was expanded to include additional funding for PEP of pulmonary anthrax, bringing the total value up to approximately $304 million.

For more information, visit www.ParatekPharma.com or follow us on LinkedIn and Twitter.

CONTACT:           

For Investors:                    
Hans Vitzthum
LifeSci Advisors
ir@ParatekPharma.com 
Phone: 617-430-7578                    

For Media:
Christine Fanelle
Scient PR
christine@scientpr.com 
Phone: 215-595-5211 

FAQ

What stock options were granted by Paratek Pharmaceuticals?

Paratek granted stock options totaling 9,700 shares at an exercise price of $4.86 to five new employees.

What is the vesting schedule for the new stock options?

The stock options will vest over a four-year period, with 25% vesting after 12 months.

How many restricted stock units were granted by Paratek?

Paratek granted a total of 9,600 restricted stock units that will vest after 36 months.

What is the significance of the BARDA contract for Paratek?

The BARDA contract, now valued at approximately $304 million, supports the development of NUZYRA for pulmonary anthrax.

When was the stock option grant announced?

The stock option grant was announced on September 30, 2021.